33results about How to "Promote differentiation and maturation" patented technology

The invention relates to a method for culturing gamma-delta-T cells, and in particular relates to a method for in-vitro amplification of gamma-delta-T cells, wherein the method comprises the following operating steps of: pre-coating a T75 culture bottle by a TCR-gamma-delta resisting antibody and CD28McAb for later use use; isolating the peripheral blood mononuclear cell (PBMC) of a patient; regulating the PBMC concentration to 1*10<6> 6 / ml by a serum-free culture medium which contains 5% of autologous plasma, and transferring PBMC cell suspension into the T75 culture bottle; adding an initial culture medium which contains proper concentrations of Zoledronat, HSP70, 1L-2, 1L-7 and 1L-15; culturing in a saturated humid environment containing 5% of CO2 at 37 DEG C; depending on growth situation of the cell, changing the culture medium every 2-3days, to control the cell concentration at about 2.5*10<6> / ml; meanwhile, compensating full doses of Zoledronat, HSP70, 1L-2, 1L-7 and 1L-15; and continuously culturing for 12-16days, to obtain a great amount of gamma-delta-T cells which are comparatively high in purity.

The premixed feed consists of premixed mannosan preparation 0.5-2.5 wt%, premixed microbial preparation 0.5-3 wt%, bioactive peptide 1-3 wt%, fermented animal protein 30-50 wt% and organic carrier the rest. The present invention can promote growth and life activity of farm animal, replace antibiotic in raising the disease resistance of farm animal, control the growth of mildew, saccharomycetes and other hetero bacteria in feed and raise the quality of farm animal products.

The invention relates to a method for culturing gamma-delta-T cells, and more specifically relates to a method for in-vitro amplification of gamma-delta-T cells. The method comprises the following operating steps: pre-coating a T75 culture bottle with a TCR-gamma-delta resisting antibody and CD28McAb for later use; isolating peripheral blood mononuclear cells (PBMC) of patients; regulating PBMC concentration to 1*10<6> / ml with a serum-free culture medium which contains 5% of autologous plasma, and transferring the PBMC cell suspension into the T75 culture bottle; adding an initial culture medium which contains proper concentrations of Zoledronat, HSP70, Toll-like Receptors7 (TLR7) ligand, Levamisole (LMS), IL-2, IL-7 and IL-15; culturing in a saturated humid environment containing 5% of CO2 at 37 DEG C; according to growth situation of the cell, changing the culture medium every 2 to 3 days so as to control the cell concentration at about 2.5*10<6> / ml; meanwhile, compensating full doses of Zoledronat, HSP70, Toll-like Receptors7 (TLR7) ligand, Levamisole (LMS), IL-2, IL-7 and IL-15;; and continuously culturing for 12to 16 days so as to obtain a great amount of gamma-delta-T cells which are comparatively high in purity.

The invention discloses an implanting body with a multiple-size surface structure. The implanting body has the advantages that the combining strength of the implanting body and a biospy is improved, the combining time is shortened, the biological compatibility and the combining fastness are improved, and the clinical application value is higher. The implanting body comprises a micrometer-level micro structure array, wherein the surface of the implanting body is provided with nanometer-level pores, one of a micro pyramid array, a micro inverted hook array or a micro channel array is adopted as the micro structure array, the micro pyramid array comprises a plurality of pyramids which are arranged in an equidistant way, the longitudinal cross section of each pyramid is a triangle I, the micro inverted hook array comprises a plurality of inverted hooks which are arranged in the equidistant way, the longitudinal cross section of each inverted hook comprises a triangle II and a rectangle which are vertically connected, the micro channel array comprises a plurality of channels which are arranged in the equidistant way, and the longitudinal cross section of each channel is an inverted triangle.

The invention discloses a polypeptide composition for preventing and improving striae gravidarum. The composition contains one, two or three polypeptides of a polypeptide for promoting collagen synthesis and promoting epithelial regeneration, a polypeptide for supplementing fibronectin and a polypeptide for promoting elastin synthesis, and one or two polypeptides of a polypeptide for reducing inflammatory response and tightening the skin and a polypeptide for delaying skin aging and raising defensive power of the skin. The polypeptide composition of the invention is safe to human body, has noirritating or toxic or side effect, can repair epidermis, basilar membrane and dermis of the skin, diminish inflammation, promote growth of connective tissues and increase generation of collagen and elastin, and can be used for antenatal prevention and postnatal repair of striae gravidarum.

The invention provides a preparation method of a composite artificial bone material. The preparation method includes steps: (1) dissolving PLGA into an organic solvent, adding nano hydroxyapatite and beta-tricalcium phosphate, and well mixing to obtain 3D printing ink; (2) subjecting the 3D printing ink to low-temperature deposition printing by 3D printing equipment, and performing freeze drying to obtain a porous bone scaffold; (3) performing negative-pressure pouring of modified starch solution into the porous bone scaffold, and carrying out freeze drying to obtain the composite artificial bone material; (4) subjecting the composite artificial bone material to irradiation sterilization to obtain an artificial bone finished product. The composite artificial bone material is prepared from PLGA, nano hydroxyapatite, beta-tricalcium phosphate and modified starch by compounding, and the modified starch is capable of quickly and effectively stopping bleeding in a bone surgery process and also promoting osteoblast maturation and differentiation.

The invention relates to a stem cell and a gene engineering technique field. Embryo stem cell is provided with multidirectional differential energy, but the research and application has a plurality of ethic problems so that the research of adult stem cell with the same multidirectional differential energy is concerned, wherein the researchers attach importance to ADSC with abundant resources and a convenient extraction. FGF10 is an adult fiber cell growth factor which only expresses white fat tissue and has the important effect for differentiating and maturing fat tissue. The invention constructs a fat stem cell line by the external culture and a recombinant vector expressing adult fiber cell growth factor10 (FGF10), exogenesis expression FGF10 accelerates differentiation and mature of ADSC by verification of external and internal experiment. The method has application prospect in the cure of skin injury, shaping and beauty field.

The invention discloses application of shikimic acid in preparing a drug for preventing or treating demyelinating diseases. In studying the effect of the shikimic acid in preventing or treating the demyelinating diseases, it is found that the shikimic acid can alleviate the severity of an inflammatory mouse demyelinating disease model induced by myelin sheath oligodendrocyte glycoprotein, improvethe demyelination lesion conditions of a focal mouse spinal cord demyelinating model induced by lysoph-osphatidylcholine, and accelerate remyelination and reduce the demyelination size by promoting oligodendrocyte progenitor cells to be differentiated into mature oligodendrocytes. As is shown by all above, the shikimic acid has a great application prospect in clinical treatment of the demyelinating diseases.

The invention belongs to the technical field of biomedicine, and relates to new medical application of interleukin-4 (IL-4) in the field of neuroscience, in particular to application of interleukin-4 in preparation of medicine for promoting neural functional recovery after acute cerebral injuries. The experimental result proves that IL-4 has an obvious neuroprotective effect on white matter lesion related nerve dysfunction caused by the acute cerebral injuries, IL-4 can promote oligodendrocyte differentiation and maturation after white matter lesion by promoting polarization of M2-type gitter cells, restoration after white matter lesion is enhanced, the neurological function is improved, the sensorimotor function is improved, and the learning dysfunction is relieved. IL-4 can be prepared into a solid or liquid pharmaceutical preparation, and the prepared pharmaceutical preparation has an obvious neuroprotective effect, and can be used for treating white matter lesion related neurologic impairment related diseases caused by the acute cerebral injuries.

The invention relates to a method for establishing an endothelial crossing model for asthmatic serum dendritic cells. The method comprises the following steps: adopting Ia centrifugation method to obtain serums, an immunomagnetic bead separation to obtain monocytes, and a trypsin digestion method to obtain human umbilical venous endothelial cells; pretreating the serums, the monocytes and the human umbilical venous endothelial cells with gelatin, adding passage endothelial cell suspension into a culture plate to grow into a single layer, suspending asthmatic patient serums on the monocytes to be added on the endothelial cell single layer, fully washing the endothelial cell single layer, and recovering suspension cells to obtain the endothelial crossing model for the asthmatic serum dendritic cells. The invention overcomes the defect that an experiment for truly simulating differentiation maturation and migration functions of the monocytes in the body of an asthmatic patient can not be carried out because of one experiment platform short. The invention provides an in vitro model depended by non cytokines for objectively simulating the monocytes to migrate and differentiate in the body to become the dendritic cells, and in addition, the asthmatic serums are a true internal environment of the patient.

The invention relates to a cationic complex liposome influenza vaccine as well as a preparation method and an application method thereof. With cationic liposome as an immune carrier and an adjuvant, the influenza vaccine comprises an immunomodulator and encapsulates an influenza vaccine antigen. The constructed cationic complex liposome influenza vaccine is 200-700nm in particle size, 5-40mV in Zeta potential, 30-90% in encapsulation efficiency, and 1-10% in drug loading capacity. The prepared cationic complex liposome influenza vaccine can significantly promote antigen uptake of dendritic cells, stimulate activation and maturation of DCs, and further cause immune response. The influenza vaccine is used for immunotherapy through intramuscular injection, subcutaneous injection or nasal mucosal administration, wherein the mucosal immune response level and the cellular immune response level of the organism are effectively enhanced through nasal mucosal administration. The influenza vaccine has a wide application prospect in influenza prevention.

The invention belongs to the field of genetic engineering and medicines, and particularly relates to a method for performing Hemopexin protein specific induction and maintaining selective polarization of microglial cells, and applications thereof in treatment of spinal cord injury repair. According to the main technical scheme, the method comprises the following steps: (I) transplanting microglial cells into Hemopexin-knockout mice spinal cord to hinder the microglial cells to be selectively polarized; and (II) co-incubating the Hemopexin protein and microglial cells to be capable of inducing and maintaining the selective polarization of the microglial cells. The Hemopexin-induced microglial cells show an M2 phenotype, so that the repair of the spinal cord nerve injury can be effectively promoted.

The invention relates to the field of antitumor drugs, and in particular relates to an application of quetiapine fumarate in preparing a medicine for treating glioma. Through in-vivo and in-vitro experiments, the effects of resisting glioma and glioma stem cells of quetiapine fumarate (KUI) and the effects obtained by mixing KUI with chemotherapy drug temozolomide (TMZ) are investigated; quetiapine fumarate can inhibit growth of glioma, and promote the glioma stem cells to express markers of oligodendroglia cells, and after being mixed with TMZ for application, quetiapine fumarate increases the sensitivity of the glioma cells for temozolomide, and the inbibiting effect is better; after temozolomide acts, quetiapine fumarate can delay the growth of recurrent glioma; quetiapine fumarate can promote the glioma stem cells to differentiate and mature towards the oligodendroglia like cells by taking the glioma stem cells as the action target. Therefore, quetiapine fumarate can be used for preparing the medicine for treating glioma, and achieves good effects for treating and prognosis of glioma.

A person who is used in the field of medicine- Preparation of human cell fusion maternal-fetal blood group incompatibility therapy hybrid strain, characterized by, Using erythropoietin as inducer, ''O'' type human bone marrow cell positive for Rh were cultured, to increase the number of directionally developing erythroid cells, human bone marrow cells and human myeloma cells were fused into hybridized cells, Erythropoietin was use to induce that directional differentiation of the hybridized cell, Hybrid cell clones were screened by HAT, The hybridization strains of Rh positive cells which canbe expanded indefinitely in vitro were screened by Rh antibody, As that adsorbent aft industrialized amplification, A low-cost and safe method for that treatment of maternal-fetal blood group incompatibility hemolytic disease without plasma exchange solution without remove plasma and its beneficial ingredients is create by absorbing pathogenic Rh antibody in peripheral plasma of pregnant women with maternal-fetal blood group incompatibility through an in vitro adsorption device which is formed by an adsorber and a blood separator.

The invention relates to a compound nutritional formula for regulating and nourishing kidney and a preparation method thereof, and belongs to the field of nutritional food. The compound nutritional formula comprises astragalus root, raw oyster, dogwood, dark plum, sophora flower, coix seed, gordon euryale seed, lotus seed, artichoke, eucommia bark, leek seed, medlar, donkey-hide gelatin, sealwort,yam, poria cocos, kudzu root, meson, lily, seabuckthorn, fried black wormwood, dandelion, dendrobium, adenophora root, fragrant solomonseal rhizome, lotus seed, inulin polysaccharide, elsholtzia chinensis, endothelium corneum gigeriae galli, walnut kernel, alginate, protein peptide, arabinose and xylitol. The compound nutrition formula for regulating and nourishing kidney and the preparation method thereof has the advantages of balancing and lowering urinary protein, uric acid, urobilinogen, urinary creatinine and urea nitrogen, improving kidney blood supply and supplementing kidney qi, reducing blood sugar, lowering blood pressure, relaxing blood vessels, promoting formation of ossein, enhancing bone density, promoting differentiation and maturation of immune cells, repairing damaged nerve, muscle and meat skin, promoting wound healing; arabinose can inhibit glucose absorption by small intestine by arabinose, reduce blood sugar, relieve alcoholic intoxication, protect liver, inhibitobesity, and reduce uric acid and gout.

The invention relates to an mRNA (messenger Ribonucleic Acid) tumor vaccine for improving DCs (Dendritic Cancer) disability in a tumor immune microenvironment as well as a preparation method and application thereof. The mRNA tumor vaccine is constructed from a cation compound loaded with alpha-galactosylceramide (alpha-Galcer), protamine and mRNA, the alpha-Galcer is adsorbed to a phospholipid layer of the compound, and a protamine-HER2 mRNA condensation compound is wrapped in an inner core of the compound. The mRNA tumor vaccine constructed by the invention can be used for immunotherapy through subcutaneous injection or intramuscular injection or nasal mucosa, and can stimulate DCs cells to be mature and secrete cell factors. After mice are immunized, the novel mRNA tumor vaccine can effectively promote T cell proliferation and activation, exert congenital and adaptive immune response, improve the inhibition effect of a tumor immune microenvironment and effectively enhance anti-tumor immune response.

The invention relates to the field of biological virus construction and particularly discloses a recombinant oncolytic Newcastle disease virus for expressing human GM-CSF. The recombinant oncolytic Newcastle disease virus is obtained by inserting a human GM-CSF coding gene into a full-length genome plasmid of a Newcastle disease virus Italien strain and reviving the virus in vitro. The human GM-CSF gene is as shown in SEQ ID NO.1. A GM-CSF molecule is used for recruiting DC cells from mononuclear cells, activating neutrophil and promoting differentiation and maturation of the DC cells, especially has an important effect on promoting processing and presentation of antigens, combines a characteristic of selective replication of tumors of the oncolytic Newcastle disease virus, directly kills tumor cells, causes inflammation, recruits more DC cells, promotes maturation of the DC cells and presentation of tumor antigens, enhances local and whole-body anti-tumor immune responses of tumors, improves a treatment effect of single or combined use of the oncolytic virus in treating solid tumors, and brings a new treatment thought for tumor immunotherapy.

The invention belongs to the field of biological medicine and the technical field of cell therapy, and particularly relates to a method for efficiently amplifying NK and transfecting NKG2D activated NK cells in vitro. The method comprises the following specific steps: optimizing an NK cell in-vitro efficient amplification technology and detecting NK immune biological characteristics; the method comprises the following steps: detecting mRNA expression of NKG2D ligands MICA and ULBP 1, 2 and 3 in tumor cells and tumor tissues by using an RT-PCR method; performing construction of an NKG2D cloning vector; performing construction of an NKG2D eukaryotic expression vector; expressing and identifying the eukaryotic expression vector in CHO cells; the eukaryotic expression vector transfects NK cells and influences the biological functions of the NK cells. The invention provides a method for constructing a pEGFP-N1 / NKG2D eukaryotic fluorescent expression vector by using a genetic engineering technology, transfecting NK cells with the constructed pEGFP-N1 / NKG2D plasmids, detecting the proliferation situation of the NK cells before and after NKG2D transfection and the killing effect on tumor cell lines by using an MTT method, detecting the mRNA expression level of related killing molecules IL-2, TNF-a, Perforin and TWEAK by using an RT-PCR method. The method for efficiently amplifying the NK in vitro and transfecting the NKG2D activated NK cells, which is a new thought, is provided for tumor treatment.

The invention relates to a cationic liposome influenza vaccine capable of entrapping quantum dots and a preparation method thereof. The cationic liposome influenza vaccine adopts a cationic complex asa vaccine adjuvant and a carrier, and is prepared by entrapping the quantum dots and influenza vaccine stock into the cationic liposome complex by adopting a film scattering method, a freeze-thaw method or a freeze drying method; and the particle size of the obtained cationic liposome influenza vaccine is between 100nm and 3 micrometers, a zeta potential is 30 to 90 mV, the entrapping rate is 45percent to 95 percent, and the drug carrying capacity is 2 to 10 percent. The cationic liposome influenza vaccine entrapping the quantum dots prepared by the invention can be used as a biological probe to capture and image cells and is good in stability; and by virtue of the immunization of mouse nasal mucosa, the novel vaccine can significantly improve the mouse humoral immunity and mucosal immunity response levels.

A method for culturing autologous tissue engineered epidermis, using umbilical cord mesenchymal cells as trophoblast cells. The advantage of the present invention is that by using umbilical cord mesenchymal cells as trophoblast cells, and at the same time cooperating with the serum-free medium of the present invention, there is no need to replace it with a differentiation medium, reducing the consumption of manpower, financial resources and time; Prepared with glue to avoid secondary digestion of the epidermal tissue by enzymes, reduce damage to cell activity, and accelerate the peeling speed between the epidermal tissue and the culture plate.

The invention discloses an anti-season fruit mulberry fallen leaf treatment method. The method comprises the steps of cutting in advance, promoting branch aging and spraying fallen leaf promoting liquid medicine. The fallen leaf promoting liquid medicine is prepared from ethephon and paclobutrazol. According to the method, pruning, water and fertilizer management and leaf falling promoting treatment are matched, so that leaves of the fruit mulberries can fall according to a production plan, flower buds of the fruit mulberries can be promoted to be differentiated and aged, and preconditions are created for promoting the fruit mulberries to blossom and bear fruits according to the plan. In a word, the method is simple and low in cost, does not damage mulberry leaf buds and flower buds, provides technical support for developing out-of-season mulberries and achieving mulberry yield adjustment, and has wide application prospects.

A maternal-fetal blood group incompatibility treatment device based on clearance of pathogenic antibodies for use in the medical field is characterized in that, erythropoietin is used as inducer, ''O'' type human or monkey bone marrow cell positive for Rh were cultured, to increase the number of directionally developing erythroid cells, human or monkey bone marrow cells were fused with mouse or human myeloma cells to form hybridized cells, different concentrations of erythropoietin were selected according to different fusion cells, to induce the directional differentiation of hybridized cells,Hybrid cell clones were screened by HAT, The hybridization strains of Rh positive cells which can be expanded indefinitely in vitro were screened by Rh antibody, after industrial amplification, it isused as an adsorbent to make an adsorber and then a blood separator to form an in vitro therapeutic device. By adsorbing the pathogenic Rh antibody in maternal and fetal blood group incompatible maternal plasma, a cheap and safe method for the treatment of maternal and fetal blood group incompatible hemolytic disease without removing the plasma and its beneficial ingredients is established.

The invention particularly relates to application of a miR-106a-5p simulant in preparation of a bone defect repair medicine, and belongs to the field of bone repair materials. According to the miR-106a-5p simulant provided by the invention, by down-regulating Fam134a, inhibition of Fam134a on gene expression of Alp, Sp7, Col1a1 and Runx2 is relieved, osteoblast differentiation and maturation are promoted, bone defect repair is realized, and a new research direction is provided for promoting bone defect repair.

A monkey used in medicine-Preparation of mouse cell fusion maternal-fetal blood group incompatibility therapy hybrid strain, characterized by, Using erythropoietin as inducer, ''O'' type rhesus monkeybone marrow cell positive for Rh were cultured, to increase the number of directionally developing erythroid cells, and then the cultured bone marrow cells of rhesus monkey were fused with murine myeloma cells to form hybridized cells, Erythropoietin was use to induce that directional differentiation of the hybridized cell, Hybrid cell clones were screened by HAT, the hybridization strains of Rhpositive cells which can be expanded indefinitely in vitro were screened by Rh antibody, As that adsorbent aft industrialized amplification, A low-cost and safe method for that treatment of maternal-fetal blood group incompatibility hemolytic disease without plasma exchange solution without remove plasma and its beneficial ingredients is create by absorbing pathogenic Rh antibody in peripheral plasma of pregnant women with maternal-fetal blood group incompatibility through an in vitro adsorption device which is formed by an adsorber and a blood separator.

The invention provides a mixed nutrition powder for eliminating sub-health and a preparation method thereof, which belong to the technical field of nutrition and health. The technical solution adopted is a mixed nutrition powder for eliminating sub-health, and the parts by weight of each raw material are black soybean dry powder 10-25 15-30 parts of yellow millet dry powder, 5-15 parts of walnut kernel dry powder, 10-20 parts of purslane dry powder, 10-25 parts of Agaricus blazei fruiting body dry powder, and 5-20 parts of morel fruiting body dry powder. Production method: (1) Rinse black beans and yellow millet respectively, puff them, and grind them to obtain 180-200 mesh dry powder; (2) Wash and grind walnut kernels, purslane, Agaricus blazei fruiting bodies and Morchella fruiting bodies respectively , drying, and secondary grinding to obtain a dry powder of 180 mesh to 200 mesh; (3) The dry powder obtained in steps (1) and (2) is mixed according to the above weight ratio. The invention has the advantages of scientific compatibility, can nourish the kidney and spleen, enhance immunity, relieve fatigue and mental stress, etc., has a very high effect of tonifying deficiency and strengthening the body, eliminating sub-health, and the preparation method is simple and convenient to eat.